Related Content
- GSK announces divestment of OTC brands
- Dr. Reddy's launches generic asthma, allergy, bronchospasm drug
- GSK shares real-world example on how to improve switch through technology
- Prestige Brands completes remainder of GSK OTC brands acquisition
- Dr. Reddy's receives FDA approval for generic GERD treatment
HYDERABAD, India — Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.
Dr. Reddy's introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.
The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
